MIRM
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.
Mirum Pharmaceuticals, Inc. (MIRM) is rated C+ (2.6/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (B); its weakest is Value (D).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-13 | D (1.5) | B (3.5) | C+ (2.7) | C (2.4) | C+ (2.6) | C+ (2.6) |
| 2026-11-06 | B- (3.0) | B (3.5) | C+ (2.8) | C (2.5) | C+ (2.7) | B- (2.9) |
| 2026-10-30 | B- (3.0) | B (3.4) | C+ (2.8) | C (2.3) | C+ (2.7) | C+ (2.8) |
| 2026-10-23 | B- (3.0) | B (3.4) | C+ (2.8) | C (2.3) | C+ (2.6) | C+ (2.8) |
| 2026-10-16 | B- (3.0) | B (3.4) | C+ (2.8) | C (2.3) | C+ (2.6) | C+ (2.8) |